Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis A Systematic Review

被引:61
|
作者
Mueller, Jannis [1 ,2 ,3 ,4 ]
Cagol, Alessandro [1 ,2 ,3 ]
Lorscheider, Johannes [1 ,2 ,4 ]
Tsagkas, Charidimos [1 ,2 ,3 ,4 ]
Benkert, Pascal [5 ]
Yaldizli, Ozgur [1 ,2 ,3 ,4 ]
Kuhle, Jens [1 ,2 ,4 ]
Derfuss, Tobias [1 ,2 ,4 ]
Sormani, Maria Pia [6 ,7 ]
Thompson, Alan [8 ,9 ]
Granziera, Cristina [1 ,2 ,3 ,4 ]
Kappos, Ludwig [1 ,2 ,3 ,10 ]
机构
[1] Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland
[2] Univ Basel, Basel, Switzerland
[3] Univ Hosp Basel, Fac Med, Dept Biomed Engn, Translat Imaging Neurol ThINK Basel, Basel, Switzerland
[4] Univ Hosp Basel, Dept Biomed, Neurol Clin & Policlin, Basel, Switzerland
[5] Univ Basel, Univ Hosp Basel, Dept Clin Res, Clin Trial Unit, Basel, Switzerland
[6] IRCCS Osped Policlin San Martino, Dept Hlth Sci, I-16132 Genoa, Italy
[7] IRCCS Osped Policlin San Martino, Genoa, Italy
[8] UCL Inst Neurol, Queen Sq MS Ctr, London, England
[9] NIHR Univ Coll London Hosp, Biomed Res Ctr, London, England
[10] Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Spitalstr 2, CH-4031 Basel, Switzerland
关键词
DISABILITY PROGRESSION; ONSET; PIRA; ACCUMULATION; OCRELIZUMAB; AGE;
D O I
10.1001/jamaneurol.2023.3331
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
ImportanceEmerging evidence suggests that progression independent of relapse activity (PIRA) is a substantial contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (RRMS). To date, there is no uniform agreed-upon definition of PIRA, limiting the comparability of published studies.ObjectiveTo summarize the current evidence about PIRA based on a systematic review, to discuss the various terminologies used in the context of PIRA, and to propose a harmonized definition for PIRA for use in clinical practice and future trials.Evidence ReviewA literature search was conducted using the search terms multiple sclerosis, PIRA, progression independent of relapse activity, silent progression, and progression unrelated to relapses in PubMed, Embase, Cochrane, and Web of Science, published between January 1990 and December 2022.FindingsOf 119 identified single records, 48 eligible studies were analyzed. PIRA was reported to occur in roughly 5% of all patients with RRMS per annum, causing at least 50% of all disability accrual events in typical RRMS. The proportion of PIRA vs relapse-associated worsening increased with age, longer disease duration, and, despite lower absolute event numbers, potent suppression of relapses by highly effective disease-modifying therapy. However, different studies used various definitions of PIRA, rendering the comparability of studies difficult.Conclusion and RelevancePIRA is the most frequent manifestation of disability accumulation across the full spectrum of traditional MS phenotypes, including clinically isolated syndrome and early RRMS. The harmonized definition suggested here may improve the comparability of results in current and future cohorts and data sets.
引用
收藏
页码:1232 / 1245
页数:14
相关论文
共 50 条
  • [41] Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate
    von Wyl, Viktor
    Benkert, Pascal
    Moser, Andre
    Lorscheider, Johannes
    Decard, Bernhard
    Hanni, Peter
    Lienert, Carmen
    Kuhle, Jens
    Derfuss, Tobias
    Kappos, Ludwig
    Yaldizli, Ozgur
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (03) : 439 - 448
  • [42] Cerebellar and/or Brainstem Lesions Indicate Poor Prognosis in Multiple Sclerosis: A Systematic Review
    Yang, Yuyuan
    Wang, Meng
    Xu, Lulu
    Zhong, Meixiang
    Wang, Yajuan
    Luan, Moxin
    Li, Xingao
    Zheng, Xueping
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [43] Multiple sclerosis in Indigenous Peoples of the Americas: A systematic review of incidence, prevalence, and outcomes
    Robers, Michael, V
    Hurtubise, Brigitte
    Roberts, Melissa H.
    Robinson, Rheanna
    Schmidt, Hollie
    Amezcua, Lilyana
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 72
  • [44] Sleep in multiple sclerosis: a systematic review and meta-analysis of polysomnographic findings
    Zhang, Ye
    Ren, Rong
    Yang, Linghui
    Zhang, Haipeng
    Shi, Yuan
    V. Vitiello, Michael
    Sanford, Larry D.
    Tang, Xiangdong
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2023, 19 (02): : 253 - 265
  • [45] Circular RNA in Multiple Sclerosis: Pathogenicity and Potential Biomarker Development: A Systematic Review
    Mohammed, Eiman M.
    EPIGENETICS INSIGHTS, 2023, 16
  • [46] The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses
    Claflin, Suzi B.
    Broadley, Simon
    Taylor, Bruce V.
    FRONTIERS IN NEUROLOGY, 2019, 9
  • [47] Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis
    Oechtering, Johanna
    Schaedelin, Sabine
    Benkert, Pascal
    Mueller, Stefanie
    Achtnichts, Lutz
    Vehoff, Jochen
    Disanto, Giulio
    Findling, Oliver
    Fischer-Barnicol, Bettina
    Orleth, Annette
    Chan, Andrew
    Pot, Caroline
    Barakovic, Muhamed
    Rahmanzadeh, Reza
    Galbusera, Riccardo
    Heijnen, Ingmar
    Lalive, Patrice H.
    Wuerfel, Jens
    Subramaniam, Suvitha
    Aeschbacher, Stefanie
    Conen, David
    Naegelin, Yvonne
    Maceski, Aleksandra
    Meier, Stephanie
    Berger, Klaus
    Wiendl, Heinz
    Lincke, Therese
    Lieb, Johanna
    Yaldizli, Ozgur
    Sinnecker, Tim
    Derfuss, Tobias
    Regeniter, Axel
    Zecca, Chiara
    Gobbi, Claudio
    Kappos, Ludwig
    Granziera, Cristina
    Leppert, David
    Kuhle, Jens
    ANNALS OF NEUROLOGY, 2021, 90 (03) : 477 - 489
  • [48] The association between tobacco smoking and depression and anxiety in people with multiple sclerosis: A systematic review
    Vong, Vincent
    Simpson-Yap, Steve
    Phaiju, Spreeha
    Davenport, Rebekah A.
    Neate, Sandra L.
    Pisano, Mia, I
    Reece, Jeanette C.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 70
  • [49] Systematic review of gender bias in clinical trials of monoclonal antibodies for the treatment of multiple sclerosis
    Alonso-Moreno, M.
    Ladron-Guevara, M.
    Ciudad-Gutierrez, P.
    NEUROLOGIA, 2023, 38 (09): : 695 - 706
  • [50] Clinical and radiological activity after extended interval and standard interval dosing of ocrelizumab in multiple sclerosis: A systematic review and meta-analysis
    Ghajarzadeh, Mahsa
    Rastkar, Mohsen
    Mowry, Ellen M.
    Nourbakhsh, Bardia
    NEUROLOGICAL SCIENCES, 2025,